First Line:

Central IRB #H-41609/ Prothena #NEOD001-301 (AFFIRM AL): A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis

Central IRB #H-42313/ Janssen #AMY2009 (AQUARIUS): A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis

Second+ Line:

IRB #H-39705/ Cornell Janssen DPd: Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/ Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

CIRB #H-42375/ NCI ETCTN #10440: A Phase 1/1a Study of Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis

BMC IRB #H-43903/ Columbia #AAAT8639: An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain Amyloidosis (pending)

Advarra IRB #H-43903/ AbbVie M24-209: An Open-Label Phase 1b Study Evaluating the Safety and Efficacy of ABBV-383 in AL Amyloidosis (not yet submitted to IRB)